SCHEMBL1067572

SCHEMBL1067572

COC(=O)C(CC(F)F)N1CC(Oc2ccccc2Cl)=CC1=O

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 4/20 0.36
RAB9A P51151 4/20 0.36
KMT2A Q03164 4/20 0.36
NPSR1 Q6W5P4 3/20 0.36
CXCL8 P10145 1/20 0.35
LPAR1 Q92633 1/20 0.34
LPAR5 Q9H1C0 1/20 0.34
HPGD P15428 2/20 0.34
TSHR P16473 2/20 0.34
ALDH1A1 P00352 3/20 0.34
GAA P10253 3/20 0.34
POLB P06746 2/20 0.34
SMN1; SMN2 Q16637 2/20 0.34
CYP1A2 P05177 2/20 0.34
CYP2C9 P11712 2/20 0.34
CYP2C19 P33261 2/20 0.34
MAPT P10636 2/20 0.34
CYP3A4 P08684 1/20 0.34
HTT P42858 1/20 0.34
MEN1 O00255 2/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2700658 0.91 NPSR1 (0.38) NPC1RAB9AKMT2ANPSR1CXCL8
SCHEMBL1064483 0.91 NPSR1 (0.38) NPC1RAB9AKMT2ANPSR1CXCL8
SCHEMBL1066903 0.90 NPC1 (0.35) NPC1RAB9AKMT2ANPSR1CXCL8
SCHEMBL1063746 0.88 CXCL8 (0.40) NPC1RAB9AKMT2ANPSR1CXCL8
SCHEMBL1066491 0.88 NPC1 (0.34) NPC1RAB9AKMT2ANPSR1CXCL8
SCHEMBL1066557 0.87 NPC1 (0.35) NPC1RAB9AKMT2ANPSR1CXCL8
SCHEMBL1066354 0.86 NPC1 (0.35) NPC1RAB9AKMT2ANPSR1CXCL8
SCHEMBL1068593 0.86 NPC1 (0.37) NPC1RAB9AKMT2ANPSR1CXCL8
SCHEMBL1066913 0.86 NPC1 (0.35) NPC1RAB9AKMT2ANPSR1CXCL8
SCHEMBL1068624 0.85 HPGD (0.41) NPC1RAB9AKMT2ANPSR1CXCL8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2274297-B1 PYRROLIDINONE GLUCOKINASE ACTIVATORS HOFFMANN LA ROCHE (CH) 2012-05-09 EP disclosed
EP-2274297-A1 PYRROLIDINONE GLUCOKINASE ACTIVATORS F. Hoffmann-La Roche AG (CH) 2011-01-19 EP disclosed
US-7741327-B2 Pyrrolidinone glucokinase activators HOFFMANN-LA ROCHE INC. (US) 2010-06-22 US disclosed
US-20090264445-A1 PYRROLIDINONE GLUCOKINASE ACTIVATORS BERTHEL STEVEN JOSEPH 2009-10-22 US disclosed
WO-2009127546-A1 PYRROLIDINONE GLUCOKINASE ACTIVATORS F. HOFFMANN-LA ROCHE AG (CH) 2009-10-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090264445-A1 PYRROLIDINONE GLUCOKINASE ACTIVATORS GCKR, GCK, PDK2 NPC1 3656/4885RAB9A 2842/4885KMT2A 2072/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.